PSI CRO, 21 November 2024 – PSI, a Swiss-based global full-service contract research organization focused on on-time clinical trial enrollment (CRO), has relocated its Kazakhstan team office to the Ken Dala Business Center, 4th Floor, 38 Dostyk Avenue, Almaty, A25D9D1, Kazakhstan. The new office marks the CRO’s continued growth in both its local country team, which now consists of 14 operational members (with more on the way) supporting global pivotal trials, and the greater Asia-Pacific region.
The office is centrally located near the downtown area of Almaty, a popular hub for local and international businesses. The growth of clinical research and pharmaceutical production in the country has been steadily rising in recent years, with growing clinical trial support from the country’s research, academic, and medical organizations in 2021 and 2022, reflecting the country’s increasing international presence.*
“Achieving on-time delivery for our sponsors through local site relationships is what makes PSI unique,” said Dauren Mukatayev, PSI Country Manager. “Moving to the new office has offered a wonderful space for the team to continue expanding, helping us provide additional support and strengthen our relationships with local sponsors, sites, and investigators. We couldn’t be more thrilled with the move.”
To learn more about PSI’s recent growth and full-service CRO capabilities, visit psi-cro.com/contact/.
About PSI: PSI CRO is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI’s global reach supports clinical trials across multiple countries and continents and specializes in the planning and execution of global pivotal registration clinical trials. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors.
Global headquarters are located in Switzerland at 113a Baarerstrasse, Zug 6300. www.psi-cro.com
For Media Inquiries
Paul Mirek
*Buntz B. Why Kazakhstan and Georgia could be clinical trial hotspots. Drug Discovery and Development. November 8, 2022. https://www.drugdiscoverytrends.com/why-kazakhstan-and-georgia-could-be-clinical-trial-hubs-in-the-future/.
